Bilibrubin rise with Zytiga/Lupron

[ronton2]

I have been taking Zytiga/Lupron for nearly six months. Excellent results: PSA undetectable at this stage. One exception: my bilirubin count has risen twice since starting this regimen and my oncologist suggested that my daily atorvastatin 40mg might be reacting with the Zytiga, causing the bump. Has anyone in this amazing braintrust--so grateful I found this site--experienced this?

[Chiquis]

My husband has been taking Zytiga since September he also takes Atorvastatin. I noticed as well his bilirubin in the first blood test since taking Zytiga was 1.3 and the last one 2.0. So it's definitely going up. Haven't discussed it with the MD since according to him, all his blood tests have come out normal. But I'm a little on the edge about it. The best to you.

Sincerely,

Erika

[Hidden]

How high is it? What about other liver enzymes such as AST, ALT, and ALK PHOS? Do you know if they are in range?

[ronton2 in reply to Hidden]

Gregg, all other enzymes are just fine. Only bilirubin is @ 1.8

[ronton2 in reply to ronton2]

Add to Gregg: I checked on line for liver toxicity levels and will now be better able to determine whether I remain mildly elevated or not.

[ctarleton]

I have not taken Zytiga, but here's the general overview blurb for monitoring liver function tests and modifying Zytiga dosages if liver toxicity (from drug interactions or other causes) is suspected/confirmed.

"Hepatotoxicity - In postmarketing experience, there have been ZYTIGA®-associated severe hepatic toxicities, including fulminant hepatitis, acute liver failure and deaths. Monitor liver function and modify, withhold, or discontinue ZYTIGA® dosing as recommended (see Prescribing Information for more information). Measure serum transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] and bilirubin levels prior to starting treatment with ZYTIGA®, every two weeks for the first three months of treatment, and monthly thereafter. Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs suggestive of hepatotoxicity develop. Elevations of AST, ALT, or bilirubin from the patient's baseline should prompt more frequent monitoring. If at any time AST or ALT rise above five times the upper limit of normal (ULN) or the bilirubin rises above three times the ULN, interrupt ZYTIGA® treatment and closely monitor liver function. Re-treatment with ZYTIGA® at a reduced dose level may take place only after return of liver function tests to the patient’s baseline or to AST and ALT less than or equal to 2.5X ULN and total bilirubin less than or equal to 1.5X ULN.

Permanently discontinue ZYTIGA® for patients who develop a concurrent elevation of ALT greater than 3X ULN and total bilirubin greater than 2X ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation. "

For full details see:

zytigahcp.com/dosing-and-mo...

Charles

[ronton2 in reply to ctarleton]

Charles, thanks for the post. I am relieved so far but based on what you say must have it monitored carefully.

[ronton2]

Thanks, Nalakrats, will ldo

[ronton2]

I will try the Milkweek and Dandelion. It certainly seems a wise move at this point. Many thanks for the advice, Dr. N.